A good time to buy, Vyome Holdings (NASADAQ: HIND) acquires Oculo Health

Vyome Holdings Inc. (HIND) acquired substantially all assets of Oculo Inc., an artificial intelligence startup launched at the Massachusetts Institute of Technology, according to a company statement.

The clinical-stage healthcare holding company launched a new business unit focused on using AI to address inflammation. The unit will use Oculo’s assets to develop an AI psychiatrist trained on data from the United States and India.

A newly formed Vyome Board of Directors AI subcommittee will oversee the business unit. The committee comprises Krishna Gupta, Mohanjit Jolly, and Stash Pomichter, all MIT alumni with AI expertise.

“Inflammation is currently one of the biggest health crises facing humanity, and we intend to attack the condition from all angles in order to limit the usage of steroids,” said Stash Pomichter, a Vyome director. “We envision an AI psychiatrist that can diagnose and help treat systemic inflammation by targeting behavioral drivers and biomarkers.”

The company plans to establish what it calls a therapeutic category combining mental health, psychoneuroimmunology, and digital health, with commercialization beginning in the US and India.

Alay Shah, founder of Oculo, said his company was launched to build at the intersection of the human body and mind, quantifying mental processes using AI advances.

The acquisition will not affect progress on Vyome’s existing biotech assets, the company stated. Vyome remains funded through 2026 to advance its core business operations.

Mohanjit Jolly, a Vyome director and partner at Iron Pillar, cited the digital therapeutics market potential, suggesting it could exceed $100 billion over the next decade for products that reduce reliance on biologics or other drugs.